SEC Filings

Form 10-Q
BEIGENE, LTD. filed this Form 10-Q on 08/09/2018
Document Outline
Entire Document (6623.9 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - BeiGene, Ltd.
Page 3 - PART I. FINANCIAL INFORMATION
Page 4 - BEIGENE, LTD.
Page 5 - BEIGENE, LTD.
Page 6 - BEIGENE, LTD.
Page 7 - BEIGENE, LTD.
Page 8 - Use of estimates
Page 9 - Announcements and Observer Comments (SEC Update)Income Statement Reporting Comprehensive Income (Top
Page 10 - Statement of Cash Flows: Restricted Cash,
Page 11 - Impact of adopted accounting standards
Page 12 - Significant accounting policies
Page 13 - 3. Research and Development Collaborative Arrangements
Page 14 - 4. Business Combination
Page 15 - 5. Restricted Cash and Short-term Investments
Page 16 - 7. Property and Equipment
Page 17 - 9. Land Use Right
Page 18 - 11. Income Taxes
Page 19 - 13. Long-term Bank Loan
Page 20 - 14. Shareholder Loan
Page 21 - 16. Net Loss Per Share
Page 22 - 2018 Inducement Equity Plan
Page 23 - 18. Accumulated Other Comprehensive Income/(Loss)
Page 24 - Share Subscription Agreement
Page 25 - 24. Subsequent Event
Page 26 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 27 - Recent Developments
Page 28 - Components of Operating Results
Page 29 - N/A
Page 30 - Selling, General and Administrative Expenses
Page 31 - Results of Operations
Page 32 - Cost of Sales
Page 33 - Selling, General and Administrative Expense
Page 34 - Comparison of the Six Months Ended June 30, 2018 and 2017
Page 35 - Selling, General and Administrative Expense
Page 36 - Interest Income, Net
Page 37 - Use of Funds
Page 38 - Financing Activities
Page 39 - Contractual Obligations and Commitments
Page 40 - Debt Obligations
Page 41 - Recent Accounting Pronouncements
Page 42 - Foreign Currency Exchange Rate Risk
Page 43 - Item 4. Controls and Procedures.
Page 44 - Risks Related to Clinical Development and Regulatory Approval of Our Drug Candidates
Page 45 - *Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and r
Page 46 - N/A
Page 47 - Risks Related to Extensive Government Regulation
Page 48 - *We believe that our drug candidates designation in China as Category 1 products should confer certa
Page 49 - Chinese manufacturing facilities have historically experienced issues operating in line with establi
Page 50 - *Our drugs and any future approved drug candidates will be subject to ongoing regulatory obligations
Page 51 - *If safety, efficacy, or other issues arise with any medical product that is used in combination wit
Page 52 - *Reimbursement may not be available for our drug candidates. Even if we are able to commercialize ou
Page 53 - Recently enacted and future legislation may increase the difficulty and cost for us to obtain regula
Page 54 - Our drugs and any future approved drug candidates may fail to achieve the degree of market acceptanc
Page 55 - *We have limited experience in marketing third-party drugs and no experience in launching an interna
Page 56 - We face substantial competition, which may result in others discovering, developing or commercializi
Page 57 - and other jurisdictions, which could expose us to criminal sanctions, civil penalties, contractual d
Page 58 - The illegal distribution and sale by third parties of counterfeit versions of our drugs or stolen pr
Page 59 - *We have incurred significant net losses since our inception and anticipate that we will continue to
Page 60 - *Raising additional capital may cause dilution to our shareholders, restrict our operations or requi
Page 61 - *Fluctuations in exchange rates could result in foreign currency exchange losses and could materiall
Page 62 - Risks Related to Our Intellectual Property
Page 63 - inter partes
Page 64 - We may not be able to protect our intellectual property rights throughout the world.
Page 65 - ex parte inter partes
Page 66 - Obtaining and maintaining our patent protection depends on compliance with various procedural, docum
Page 67 - Changes in patent law could diminish the value of patents in general, thereby impairing our ability
Page 68 - If we fail to comply with our obligations in the agreements under which we license intellectual prop
Page 69 - We expect to rely on third parties to manufacture at least a portion of our clinical and commercial
Page 70 - If third-party manufacturers fail to comply with manufacturing regulations, our financial results an
Page 71 - We have entered into collaborations, such as with Celgene and Merck KGaA, Darmstadt Germany, and may
Page 72 - N/A
Page 73 - *If we fail to maintain an effective distribution channel for our products, our business and sales o
Page 74 - *We have significantly increased the size and capabilities of our organization, and we may experienc
Page 75 - *We incur significant costs as a result of operating as a public company in the United States, and o
Page 76 - *If we fail to comply with the U.S. Foreign Corrupt Practices Act or other anti-bribery laws, our re
Page 77 - *If we or our CROs or contract manufacturing organizations, or CMOs, fail to comply with environment
Page 78 - *If we or parties on whom we rely fail to maintain the necessary licenses for the development, produ
Page 79 - *Product liability claims or lawsuits could cause us to incur substantial liabilities.
Page 80 - N/A
Page 81 - Risks Related to Our Doing Business in the PRC
Page 82 - *Any failure to comply with PRC regulations regarding our employee equity incentive plans and invest
Page 83 - *We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any
Page 84 - *We may be treated as a resident enterprise for PRC tax purposes under the EIT Law and we may theref
Page 85 - *We and our shareholders face uncertainties with respect to indirect transfers of equity interests i
Page 86 - *Our business benefits from certain financial incentives and discretionary policies granted by local
Page 87 - Risks Related to Our American Depositary Shares and Ordinary Shares
Page 88 - *The characteristics of the U.S. capital markets and the Hong Kong capital markets are different.
Page 89 - *Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreci
Page 90 - Your voting rights as a holder of the ADSs are limited by the terms of the deposit agreement. The de
Page 91 - *Anti-takeover provisions in our constitutional documents may discourage our acquisition by a third
Page 92 - Holders of the ADSs may be subject to limitations on transfer of their ADSs.
Page 93 - Holders of the ADSs may not be able to participate in rights offerings and may experience dilution o
Page 94 - *If you are a Ten Percent Shareholder, you may be subject to adverse U.S. federal income tax consequ
Page 95 - EXHIBIT INDEX
Page 96 - N/A
Page 97 - SIGNATURES
Subdocument 2 - EX-10.1 - EX-10.1
Page 1 - Exhibit 10.1
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - Severance Benefits
Page 7 - providedhowever
Page 8 - providedhowever
Page 9 - N/A
Page 10 - /s/ John V. Oyler
Page 11 - N/A
Page 12 - Company
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Subdocument 3 - EX-10.5 - EX-10.5
Page 1 - Exhibit 10.5
Page 2 - Issuance of Ordinary Shares
Page 3 - N/A
Subdocument 4 - EX-10.7 - EX-10.7
Page 1 - Exhibit 10.7
Page 2 - Incorporation of Plan
Page 3 - RESTRICTED SHARE UNIT AWARD AGREEMENT
Page 4 - N/A
Page 5 - N/A
Page 6 - NON-QUALIFIED SHARE OPTION AGREEMENT
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - NON-QUALIFIED SHARE OPTION AGREEMENT
Page 11 - Termination as Director
Page 12 - No Right to Continue as a Director
Page 13 - NON-QUALIFIED SHARE OPTION AGREEMENT
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Subdocument 5 - EX-10.8 - EX-10.8
Page 1 - Exhibit 10.8
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - /s/ John V. Oyler
Subdocument 6 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 7 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 8 - EX-32.1 - EX-32.1
Page 1 - N/A
XBRL Item - EX-101.INS - EX-101.INS (What's this?)
XBRL Item - EX-101.SCH - EX-101.SCH (What's this?)
XBRL Item - EX-101.CAL - EX-101.CAL (What's this?)
XBRL Item - EX-101.DEF - EX-101.DEF (What's this?)
XBRL Item - EX-101.LAB - EX-101.LAB (What's this?)
XBRL Item - EX-101.PRE - EX-101.PRE (What's this?)
XBRL Viewer